PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
November 25, 2025The Journal of ImmunologyOpen Access

Targeting the Intracellular Domain of PD-L1 to Sensitize Tumors to Cytotoxic Therapy 2085

View Full Paper
Ask AI
Bookmark
Share

Authors

XTXinyi TuZLZhenkun LouHDHaidong Dong

Discussion

Loading...

Member takes

Overview

Research shows targeting PD-L1 enhances anti-tumor immunity and improves chemotherapy and radiation efficacy in triple-negative breast cancer.

Key Points

  • The aim is to explore the roles of intracellular PD-L1 and develop a novel antibody to enhance tumor response to therapies.
  • Created a PD-L1 antibody that disrupts PD-L1 and CMTM6 binding.
  • Conducted in vivo studies using patient-derived xenograft models.
  • Compared the novel antibody's performance against existing PD-L1 inhibitors in triple-negative breast cancer models.
  • Novel antibody significantly sensitized tumors to radiation and chemotherapy.
  • Outperformed traditional PD-L1 inhibitors in enhancing anti-tumor immunity.
  • Highlighted the importance of targeting intracellular PD-L1 functions.

Cite This Study

Tu et al. (2025) studied this question.

synapsesocial.com/papers/692502dc87af00ed34ac2a9fhttps://doi.org/10.1093/jimmun/vkaf283.049
View Full Paper
Ask AI
Bookmark
Share